Viva Biotech Holdings Full Year 2024 Earnings: EPS: CN¥0.078 (vs CN¥0.06 loss in FY 2023)

Viva Biotech Holdings (HKG:1873) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.99b (down 7.8% from FY 2023).
• Net income: CN¥167.3m (up from CN¥116.1m loss in FY 2023).
• Profit margin: 8.4% (up from net loss in FY 2023).
• EPS: CN¥0.078 (up from CN¥0.06 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Viva Biotech Holdings Earnings Insights

The primary driver behind last 12 months revenue was the Contract Development Manufacture Organisation (CDMO) and Commercialisation Services segment contributing a total revenue of CN¥1.18b (59% of total revenue). Notably, cost of sales worth CN¥1.30b amounted to 65% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥257.5m (50% of total expenses). Explore how 1873's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Hong Kong.

Performance of the Hong Kong Life Sciences industry.

The company's shares are up 9.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Viva Biotech Holdings (of which 1 is a bit unpleasant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.